CSL Behring is a global biotherapeutics leader driven by our promise to save lives. We meet patients’ needs using the latest technologies to develop and deliver innovative therapies. The company offers the broadest range of products in the industry for treating coagulation disorders, primary immune deficiencies, hereditary angioedema, inherited respiratory disease, and neurological disorders. CSL Behring’s products are also used in cardiac surgery, organ transplantation, burn treatment and more
Products
Events
Booth:
2.16 - 2.19
Tue, 16 Mar 2021 - Fri, 19 Mar 2021
News
Pathophysiology of Trauma and Revised European Trauma Guidelines
2019 26 Sep
The fifth edition of the European Trauma Treatment Guidelines that have already been cited 1650 times and downloaded from the original home page nearly 600,000 times. The European trauma treatment guidelines have significantly changed the treatment modalities of trauma patients around the world. The guidelines have also been endorsed... Read more
Coagulopathy During Cardiac Surgery: The Role of Factor Concentrates
2019 26 Sep
The EACTS/EACTA Guidelines on patient blood management for adult cardiac surgery. The EACTS/EACTA guidelines were published jointly by the Society of Cardiothoracic Anesthesia and Cardiac Surgery for patient blood management. In the bleeding patient with a low fibrinogen level (<1.5 g/L), fibrinogen substitution may be considered to reduce... Read more
Treatment Options for Factor-Xa Inhibitor-Related Bleeding
2019 26 Sep
Specific treatment options for factor Xa inhibitor-related bleeding, focusing on drugs like rivaroxaban, apixaban, and edoxaban. Non-vitamin K oral anticoagulants (NOACs/DOACs) are direct reversible inhibitors of factor Xa. These drugs are also reversible inhibitors versus warfarin or other vitamin K antagonist that are used in Europe. Anticoagulants... Read more
Factor Concentrates in the Perioperative Management of Coagulopathy
2019 26 Sep
Pathophysiology of Trauma and Revised European Trauma Guidelines Prof. Donat R. Spahn Coagulopathy During Cardiac Surgery: The Role of Factor Concentrates Marco Ranucci Treatment Options for Factor-Xa Inhibitor-Related Bleeding Jerrold Levy Read more
Key decisions in a goal-directed coagulation management approach
2018 16 Oct
An individualised goal-directed approach to managing coagulopathy is recommended to treat bleeding trauma patients. Severe trauma is a great burden to society, with millions of victims worldwide. If trauma patients are hazardly bleeding, surgical bleeding requires the surgeon to fix the problem, while coagulopathy requires management... Read more
Evidence for using first-line coagulation factor concentrates for trauma- induced coagulopathy
2018 16 Oct
Fibrinogen limits coagulopathy and massive bleeding, has less transfusion requirements and thereby decreases the risk of multi-organ failure in trauma patients. What stops the bleeding? Haemostatic therapy aims to stop the bleeding, but is it a concentration of coagulation factors, mainly assessed by international normalised ratio (INR)... Read more
Implementation of a revised trauma management protocol
2018 16 Oct
Goal-directed therapy of coagulopathy is recommended for trauma patients. Can guidelines direct our strategy? When presented with bleeding trauma patients, our management strategy may be directed by guidelines, e.g. the European trauma guideline (Rossaint et al. 2016). This recommends treatment with fibrinogen concentrate or cryoprecipitate... Read more
Treatment of bleeding patients during therapy with direct oral anticoagulants
2017 15 Sep
Results from the French registry: GIHP-NACO Presents results from a registry detailing information about the management of bleeding patients in the emergency room, operating room or intensive care unit during therapy with direct oral anticoagulants. Background There is a large literature on the efficacy of direct oral anticoagulants... Read more
Fibrinogen concentrate in elective complex cardiac surgery: a monocentric trial
2017 15 Sep
Presents the results from a randomised controlled trial which aimed to determine if fibrinogen concentrate infusion reduces intraoperative blood loss in cardiac surgery patients. Background Excessive bleeding is a common complication in cardiac surgery, and may result in the need for red blood cell (RBC) transfusion. Intraoperative... Read more
Treatment of trauma-induced coagulopathy with factor concentrates
2017 15 Sep
RETIC study Presents results of the RETIC study that compared treatment of trauma-induced coagulopathy using coagulation factor concentrates or fresh frozen plasma. Background Trauma-induced coagulopathy (TIC) represents a clinical picture resulting from severity of injury, hypoperfusion, blood loss, consumption, dilution and... Read more
Jobs not available
Catalogue
Catalogue not available
Emil-von-Behring Straße,
Marburg
35041
Germany
+49 (0) 6421 39-12
White Papers - Case Studies
Not available
Videos
Videos not available
Articles
Pathophysiology of Trauma and Revised European Trauma Guidelines
2019 26 Sep
The fifth edition of the European Trauma Treatment Guidelines that have already been cited 1650 times and downloaded from the original home page nearly 600,000 times. The European trauma treatment guidelines have significantly changed the treatment modalities of trauma patients around the world. The guidelines have also been endorsed... Read more
Coagulopathy During Cardiac Surgery: The Role of Factor Concentrates
2019 26 Sep
The EACTS/EACTA Guidelines on patient blood management for adult cardiac surgery. The EACTS/EACTA guidelines were published jointly by the Society of Cardiothoracic Anesthesia and Cardiac Surgery for patient blood management. In the bleeding patient with a low fibrinogen level (<1.5 g/L), fibrinogen substitution may be considered to reduce... Read more
Treatment Options for Factor-Xa Inhibitor-Related Bleeding
2019 26 Sep
Specific treatment options for factor Xa inhibitor-related bleeding, focusing on drugs like rivaroxaban, apixaban, and edoxaban. Non-vitamin K oral anticoagulants (NOACs/DOACs) are direct reversible inhibitors of factor Xa. These drugs are also reversible inhibitors versus warfarin or other vitamin K antagonist that are used in Europe. Anticoagulants... Read more
Factor Concentrates in the Perioperative Management of Coagulopathy
2019 26 Sep
Pathophysiology of Trauma and Revised European Trauma Guidelines Prof. Donat R. Spahn Coagulopathy During Cardiac Surgery: The Role of Factor Concentrates Marco Ranucci Treatment Options for Factor-Xa Inhibitor-Related Bleeding Jerrold Levy Read more
Key decisions in a goal-directed coagulation management approach
2018 16 Oct
An individualised goal-directed approach to managing coagulopathy is recommended to treat bleeding trauma patients. Severe trauma is a great burden to society, with millions of victims worldwide. If trauma patients are hazardly bleeding, surgical bleeding requires the surgeon to fix the problem, while coagulopathy requires management... Read more
Evidence for using first-line coagulation factor concentrates for trauma- induced coagulopathy
2018 16 Oct
Fibrinogen limits coagulopathy and massive bleeding, has less transfusion requirements and thereby decreases the risk of multi-organ failure in trauma patients. What stops the bleeding? Haemostatic therapy aims to stop the bleeding, but is it a concentration of coagulation factors, mainly assessed by international normalised ratio (INR)... Read more
Implementation of a revised trauma management protocol
2018 16 Oct
Goal-directed therapy of coagulopathy is recommended for trauma patients. Can guidelines direct our strategy? When presented with bleeding trauma patients, our management strategy may be directed by guidelines, e.g. the European trauma guideline (Rossaint et al. 2016). This recommends treatment with fibrinogen concentrate or cryoprecipitate... Read more
Treatment of bleeding patients during therapy with direct oral anticoagulants
2017 15 Sep
Results from the French registry: GIHP-NACO Presents results from a registry detailing information about the management of bleeding patients in the emergency room, operating room or intensive care unit during therapy with direct oral anticoagulants. Background There is a large literature on the efficacy of direct oral anticoagulants... Read more
Fibrinogen concentrate in elective complex cardiac surgery: a monocentric trial
2017 15 Sep
Presents the results from a randomised controlled trial which aimed to determine if fibrinogen concentrate infusion reduces intraoperative blood loss in cardiac surgery patients. Background Excessive bleeding is a common complication in cardiac surgery, and may result in the need for red blood cell (RBC) transfusion. Intraoperative... Read more
Treatment of trauma-induced coagulopathy with factor concentrates
2017 15 Sep
RETIC study Presents results of the RETIC study that compared treatment of trauma-induced coagulopathy using coagulation factor concentrates or fresh frozen plasma. Background Trauma-induced coagulopathy (TIC) represents a clinical picture resulting from severity of injury, hypoperfusion, blood loss, consumption, dilution and... Read more
CSL Behring Special Symposium Euroanaesthesia 2019
Special Supplement in collaboration with CSL Behring
CSL Behring: Supplement from Euroanaesthesia 2017 Symposium
